Does the media favor MIRM or GHRS?

In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than GH Research. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 2 mentions for GH Research. Mirum Pharmaceuticals' average media sentiment score of 1.41 beat GH Research's score of 0.94 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GH Research 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GHRS or TGTX?

In the previous week, TG Therapeutics had 10 more articles in the media than GH Research. MarketBeat recorded 12 mentions for TG Therapeutics and 2 mentions for GH Research. GH Research's average media sentiment score of 0.94 beat TG Therapeutics' score of 0.62 indicating that GH Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is CNTA or GHRS more profitable?

GH Research's return on equity of -19.36% beat Centessa Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Centessa Pharmaceuticals N/A -60.37% -44.17% GH Research N/A -19.36% -18.73%

Does the media refer more to CNTA or GHRS?

In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than GH Research. MarketBeat recorded 4 mentions for Centessa Pharmaceuticals and 2 mentions for GH Research. Centessa Pharmaceuticals' average media sentiment score of 1.33 beat GH Research's score of 0.94 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GH Research 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, COGT or GHRS?

GH Research is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A GH Research N/A N/A -$48.26M -$0.92 N/A

Is COGT or GHRS more profitable?

GH Research's return on equity of -19.36% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% GH Research N/A -19.36% -18.73%

Does the media refer more to COGT or GHRS?

In the previous week, Cogent Biosciences had 5 more articles in the media than GH Research. MarketBeat recorded 7 mentions for Cogent Biosciences and 2 mentions for GH Research. GH Research's average media sentiment score of 0.94 beat Cogent Biosciences' score of 0.58 indicating that GH Research is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GH Research 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GHRS or PTCT?

In the previous week, PTC Therapeutics had 5 more articles in the media than GH Research. MarketBeat recorded 7 mentions for PTC Therapeutics and 2 mentions for GH Research. PTC Therapeutics' average media sentiment score of 1.37 beat GH Research's score of 0.94 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

GH Research (GHRS) Competitors

$24.46 -0.41 (-1.65%)

As of 10:48 AM Eastern

Compare

GHRS vs. MIRM, TGTX, CNTA, COGT, and PTCT

Should you buy GH Research stock or one of its competitors? MarketBeat compares GH Research with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GH Research include Mirum Pharmaceuticals (MIRM), TG Therapeutics (TGTX), Centessa Pharmaceuticals (CNTA), Cogent Biosciences (COGT), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry.

How does GH Research compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and GH Research (NASDAQ:GHRS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Mirum Pharmaceuticals has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	10.62	-$23.36M	-$13.61	N/A
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A

Mirum Pharmaceuticals has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, GH Research has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than GH Research. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 2 mentions for GH Research. Mirum Pharmaceuticals' average media sentiment score of 1.41 beat GH Research's score of 0.94 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GH Research	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.9% of GH Research shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Mirum Pharmaceuticals presently has a consensus price target of $137.64, suggesting a potential upside of 51.57%. GH Research has a consensus price target of $40.38, suggesting a potential upside of 65.07%. Given GH Research's higher possible upside, analysts clearly believe GH Research is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

GH Research has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
GH Research	N/A	-19.36%	-18.73%

Summary

Mirum Pharmaceuticals beats GH Research on 11 of the 16 factors compared between the two stocks.

How does GH Research compare to TG Therapeutics?

GH Research (NASDAQ:GHRS) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

In the previous week, TG Therapeutics had 10 more articles in the media than GH Research. MarketBeat recorded 12 mentions for TG Therapeutics and 2 mentions for GH Research. GH Research's average media sentiment score of 0.94 beat TG Therapeutics' score of 0.62 indicating that GH Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

GH Research presently has a consensus price target of $40.38, indicating a potential upside of 65.07%. TG Therapeutics has a consensus price target of $52.50, indicating a potential upside of 29.79%. Given GH Research's stronger consensus rating and higher probable upside, analysts plainly believe GH Research is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

TG Therapeutics has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A
TG Therapeutics	$616.29M	10.05	$447.18M	$2.86	14.14

TG Therapeutics has a net margin of 65.95% compared to GH Research's net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
TG Therapeutics	65.95%	88.73%	43.44%

GH Research has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

56.9% of GH Research shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

TG Therapeutics beats GH Research on 12 of the 16 factors compared between the two stocks.

How does GH Research compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and GH Research (NASDAQ:GHRS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

GH Research has lower revenue, but higher earnings than Centessa Pharmaceuticals. GH Research is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	396.16	-$197.53M	-$1.79	N/A
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A

Centessa Pharmaceuticals currently has a consensus price target of $41.33, suggesting a potential upside of 3.80%. GH Research has a consensus price target of $40.38, suggesting a potential upside of 65.07%. Given GH Research's stronger consensus rating and higher probable upside, analysts plainly believe GH Research is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than GH Research. MarketBeat recorded 4 mentions for Centessa Pharmaceuticals and 2 mentions for GH Research. Centessa Pharmaceuticals' average media sentiment score of 1.33 beat GH Research's score of 0.94 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GH Research	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Centessa Pharmaceuticals has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, GH Research has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

GH Research's return on equity of -19.36% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
GH Research	N/A	-19.36%	-18.73%

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

GH Research beats Centessa Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does GH Research compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and GH Research (NASDAQ:GHRS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

GH Research's return on equity of -19.36% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
GH Research	N/A	-19.36%	-18.73%

In the previous week, Cogent Biosciences had 5 more articles in the media than GH Research. MarketBeat recorded 7 mentions for Cogent Biosciences and 2 mentions for GH Research. GH Research's average media sentiment score of 0.94 beat Cogent Biosciences' score of 0.58 indicating that GH Research is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GH Research	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences presently has a consensus target price of $43.73, indicating a potential upside of 34.05%. GH Research has a consensus target price of $40.38, indicating a potential upside of 65.07%. Given GH Research's higher probable upside, analysts plainly believe GH Research is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Cogent Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, GH Research has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

GH Research is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A

56.9% of GH Research shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

GH Research beats Cogent Biosciences on 8 of the 13 factors compared between the two stocks.

How does GH Research compare to PTC Therapeutics?

GH Research (NASDAQ:GHRS) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

GH Research presently has a consensus target price of $40.38, suggesting a potential upside of 65.07%. PTC Therapeutics has a consensus target price of $89.00, suggesting a potential upside of 29.66%. Given GH Research's stronger consensus rating and higher possible upside, equities analysts plainly believe GH Research is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64

In the previous week, PTC Therapeutics had 5 more articles in the media than GH Research. MarketBeat recorded 7 mentions for PTC Therapeutics and 2 mentions for GH Research. PTC Therapeutics' average media sentiment score of 1.37 beat GH Research's score of 0.94 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.9% of GH Research shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

PTC Therapeutics has higher revenue and earnings than GH Research. PTC Therapeutics is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A
PTC Therapeutics	$1.73B	3.29	$682.64M	-$2.33	N/A

GH Research has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

GH Research has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. GH Research's return on equity of -19.36% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

Summary

GH Research beats PTC Therapeutics on 8 of the 15 factors compared between the two stocks.

Get GH Research News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GHRS vs. The Competition

Export

Metric	GH Research	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.68B	$3.24B	$6.25B	$12.49B
Dividend Yield	N/A	2.33%	2.69%	5.30%
P/E Ratio	-26.59	17.70	21.07	24.34
Price / Sales	N/A	324.41	556.32	125.86
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	5.42	6.56	9.78	6.76
Net Income	-$48.26M	$24.15M	$3.56B	$337.09M
7 Day Performance	9.39%	-0.45%	-0.18%	1.50%
1 Month Performance	18.11%	3.09%	4.95%	6.18%
1 Year Performance	102.48%	49.58%	28.44%	35.62%

GH Research Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GHRS GH Research	2.525 of 5 stars	$24.46 -1.6%	$40.38 +65.1%	+115.1%	$1.68B	N/A	N/A	10
MIRM Mirum Pharmaceuticals	3.8208 of 5 stars	$99.08 +0.5%	$137.08 +38.3%	+100.5%	$6.04B	$521.31M	N/A	140	Analyst Forecast Insider Trade
TGTX TG Therapeutics	3.9107 of 5 stars	$39.12 +0.6%	$52.50 +34.2%	+2.5%	$5.99B	$616.29M	13.68	290	Analyst Upgrade Gap Up
CNTA Centessa Pharmaceuticals	2.1578 of 5 stars	$39.78 +0.1%	$40.70 +2.3%	+197.5%	$5.94B	$15M	N/A	200
COGT Cogent Biosciences	3.2239 of 5 stars	$33.24 +1.7%	$43.73 +31.6%	+484.0%	$5.68B	N/A	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GHRS) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GH Research (GHRS) Competitors

GHRS vs. MIRM, TGTX, CNTA, COGT, and PTCT

How does GH Research compare to Mirum Pharmaceuticals?

Summary

How does GH Research compare to TG Therapeutics?

Summary

How does GH Research compare to Centessa Pharmaceuticals?

Summary

How does GH Research compare to Cogent Biosciences?

Summary

How does GH Research compare to PTC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS vs. The Competition

GH Research Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GH Research (GHRS) Competitors

GHRS vs. MIRM, TGTX, CNTA, COGT, and PTCT

How does GH Research compare to Mirum Pharmaceuticals?

Which has stronger earnings & valuation, MIRM or GHRS?

Which has more volatility & risk, MIRM or GHRS?

Does the media favor MIRM or GHRS?

Do insiders and institutionals have more ownership in MIRM or GHRS?

Do analysts prefer MIRM or GHRS?

Is MIRM or GHRS more profitable?

Summary

How does GH Research compare to TG Therapeutics?

Does the media favor GHRS or TGTX?

Do analysts prefer GHRS or TGTX?

Which has higher earnings and valuation, GHRS or TGTX?

Is GHRS or TGTX more profitable?

Which has more risk & volatility, GHRS or TGTX?

Do insiders & institutionals have more ownership in GHRS or TGTX?

Summary

How does GH Research compare to Centessa Pharmaceuticals?

Which has stronger earnings & valuation, CNTA or GHRS?

Do analysts recommend CNTA or GHRS?

Does the media refer more to CNTA or GHRS?

Which has more risk & volatility, CNTA or GHRS?

Is CNTA or GHRS more profitable?

Do insiders and institutionals believe in CNTA or GHRS?

Summary

How does GH Research compare to Cogent Biosciences?

Is COGT or GHRS more profitable?

Does the media refer more to COGT or GHRS?

Do analysts rate COGT or GHRS?

Which has more risk & volatility, COGT or GHRS?

Which has better valuation & earnings, COGT or GHRS?

Do institutionals and insiders have more ownership in COGT or GHRS?

Summary

How does GH Research compare to PTC Therapeutics?

Do analysts recommend GHRS or PTCT?

Does the media refer more to GHRS or PTCT?

Do institutionals and insiders hold more shares of GHRS or PTCT?

Which has preferable valuation and earnings, GHRS or PTCT?

Which has more volatility and risk, GHRS or PTCT?

Is GHRS or PTCT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS vs. The Competition

GH Research Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools